OncoCyte Corporation recently held its Q1 2025 Earnings Call, where executives and analysts gathered to discuss the company's financial performance and strategic direction. Key attendees included Joshua Riggs, President and CEO, Andrea James, CFO, and Ekkehard Schütz, Chief Science Officer, alongside analysts from BTIG LLC, Stephens Inc., Lake Street Capital Markets LLC, Needham & Co. LLC, and B. Riley Securities, Inc. During the call, CEO Joshua Riggs highlighted the company's continued progress on its 2025 plan, stating, "We've been heads down executing on our 2025 plan." Riggs expressed confidence in OncoCyte's direction, noting increased interest from potential corporate partners in their transplant and oncology technologies as "external validation" of their strategy. CFO Andrea James shared financial highlights, reporting that pharma services revenue of $2.1 million exceeded expectations. The call emphasized OncoCyte's commitment to building a valuable business through strategic investments and partnerships. The full transcript can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.